Condition
Lambert Eaton Myasthenic Syndrome
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00716066Phase 2Active Not Recruiting
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
NCT01825395UnknownPrimary
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
NCT00704925UnknownPrimary
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
NCT01377922Phase 3CompletedPrimary
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Showing all 4 trials